IDT Australia Limited provided the following market updates. Further to the Company's announcement on 22 June 2021 there has been strong media interest over the weekend regarding IDT's ongoing discussions with the Victorian Government and Monash Institute of Pharmaceutical Sciences (MIPS) with respect to IDT potentially providing cGMP manufacturing services for the production of MIPS' receptor binding domain mRNA COVID-19 vaccine candidate. IDT confirms that these discussions have recently extended to include the Commonwealth Government, the Victorian State Government and Monash University and are progressing well. On 19 March 2021 the Company announced that the Australian Government (Government), Department of Health had requested IDT to commence a feasibility assessment covering sterile facility recommissioning and sterile readiness activities. The purpose of these activities was to assess and ready IDT's sterile manufacturing facility to potentially provide additional local production capability for a COVID-19 vaccine. The Department of Health and IDT have finalised a Sterile Readiness Agreement to formalise these activities. The Key Terms of the Sterile Readiness Agreement are as follows: Scope: This agreement formalises the discussions between Health and IDT in regards to recommissioning activities to bring IDT's Melbourne based sterile manufacturing facilities into a state of sterile readiness so that IDT can use those facilities to provide assistance to Health in connection with Health's rollout of COVID-19 vaccines in Australia. Exclusivity: IDT agrees to ensure the production capacity of its sterile facility will be retained exclusively for Health or Health's nominee until the earlier of: executing a Supply Agreement to deliver a COVID-19 vaccine, or 4 months from completion of IDT's sterile readiness works. IDT expects that the remaining activities relating to the sterile facility recommissioning and sterile readiness works will continue for the next 1-2 months. At the conclusion of these activities IDT will maintain the facility in a sterile state, exclusively for the Government. During the exclusivity period the Government in its discretion can nominate a COVID-19 vaccine - in which case IDT and the relevant vaccine company would need to agree on commercial terms for the manufacture of the specific COVID-19 vaccine.